

Literatur für onkologie heute 5/2020

SCHWERPUNKT: GYNÄKOLOGISCHE TUMOREN

Systemtherapie des frühen Mammakarzinoms (S. 9–16)

C. Jackisch

1. EBCTCG. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *Lancet Oncol* 2018; 19(1): 27–39
2. www.ago-mamma.org
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 4.0. Dezember 2017; AWMF Registriernummer:032-045OL. Online: <http://www.lwtlinienprogramm-onkologie.de/leitlinien/mammakarzinom/>; Stand: 08.2018
4. von Minckwitz G et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med* 2019; 380(7): 617–628
5. Masuda N et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med* 2017; 376(22): 2147–2159
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015 Oct 3;386(10001):1341-1352
7. Schmid P, Cortes J, Pusztai L et al. Pembrolizumab for early triple negative breast cancer. *N Engl J Med* 2020; 382: 810–821
8. Spring LM et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: A systematic review and meta-analysis. *JAMA Oncol* 2016; 2(11): 1477–1486
9. Nonneville A et al. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study . *Eur J Cancer* 2017; (84): 34–43
10. Steenbruggen TG et al. Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC). *J Clin Oncol* 37, 2019 (suppl; abstr 536)
11. NCCN Guidelines Breast Cancer Version 03.2020
12. Tolaney SM et al. Seven-Year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2019; 37: 1868–1875

13. von Minckwitz G et al; APHINITY Steering Committee and Investigators Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *N Engl J Med* 2017; 377(2): 122–131
14. Sparano S et al. Long-term follow-up of the E1199 Phase-III trial evaluating the role of taxane and schedule in operable breast cancer. *J Clin Oncol* 2015; 33: 2353–2360
15. EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37.298 women with early breast cancer in 26 randomised trials. *Lancet* 2019; 393: 1440–1452
16. Möbus V et al. Ten-year results of intensive dose-dens chemotherapy show superior survival compared with conventional schedule in high-risk primary breast cancer: final results of the AGO phase III iddEPC trial. *Ann Oncol* 2018; 29: 178–185
17. Jackisch C, Blohmer JU. S3-Leitlinie: Endokrine Therapie des primären Mammakarzinoms. *Gynäkologe* 2018; 51: 548–555
18. Jackisch C et al. Assessment of quality of life in postmenopausal women with early breast cancer participating in the PACT Trial: The impact of additional patient information material packages and patient compliance *Breast Care* 2019; epub; 2019; Sept 25; doi 10.1159/000500771
19. Metzger-Fihlo O et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. *J Clin Oncol* 2015; 33: 2772–2779
20. Strasser-Weippl K et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. *Eur J Cancer* 2018; 90: 19–25
21. Sanchez-Spitmann A, Dezentje, Swen J et al. Tamoxifen Pharmacogenetics and metabolism: Results from the prospective CYPTAM Study. *J Clin Oncol* 2019; 37: 636–646
22. Moore HCF et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG Intergroup S0230. *J Natl Cancer Inst*; 111: 210–213
23. Smith I et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node positive early breast cancer: Final results of the randomized Phase III Femara versus Anastrozole Clinical Evaluation (FACE) Trial. *J Clin Oncol* 2017; 35: 1041–1048
24. Sparano JA et al. Adjuvant chemotherapy guided by a 21-Gene Expression Assay in breast cancer. *N Engl J Med* 2018; 379: 111–112
25. Sparano JA et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. *N Engl J Med* 2019; 380: 2395–2405

26. Filipitis M et al. A new molecular predictor of distant recurrence in ER-positive, Her2-negative breast cancer adds independent information to conventional clinical risk factors *Clin Cancer Res* 2011; 17: 6012–6020
27. Sestak I et al. prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. *Breast Cancer Res Treat* 2019; 176: 377–3827
28. Perou CM et al Molecular portraits of human breast tumors. *Nature* 2000; 406: 747–752
29. Sorlie T et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 2001; 98: 10869–10874
30. Caputo R et al. Gene Expression Assay in the management of early breast cancer. *Cur Med Chem* 2020; 27: 1–13
31. Varga Z, Sinn P, Seidmann AD. Summary of head-to-head comparisons of patient risk classifications by the 21-gen Recurrence Score (RS) assay and other genomic assays for early breast cancer. *Int J Cancer* 2019; 145: 882–893